Abstract
Alzheimers disease (AD) is the most common age-associated neurodegenerative disease in the world. The major neuropathological features of AD are synaptic loss, neuronal loss, neurofibrillary tangles and the deposition of amyloid- β (Aβ) as plaques and in cerebral blood vessels. Numerous Aβ targeting therapeutic approaches have been shown to prevent amyloid deposition and resulting in cognitive improvement in transgenic mouse models of AD. Some of these approaches are currently in early clinical trials. It remains to be seen if these approaches will be proven effective in patients. Future anti-AD therapies will likely be multi-modal and individually tailored depending on the patients immune status, genetic background and their amyloid burden, as determined by imaging studies using Aβ specific labeling ligands. Preclinical data suggests that it will be much more feasible to prevent AD related pathology, then to clear existing pathology, making early diagnosis critically important.
Keywords: neurotoxicity, CNS neurons, RAGE-mediated transport, tau phosphorylation, Amyloid beta Deposition
Current Pharmaceutical Design
Title: Disease Modifying Approaches for Alzheimers Pathology
Volume: 13 Issue: 19
Author(s): Marcin Sadowski and Thomas Wisniewski
Affiliation:
Keywords: neurotoxicity, CNS neurons, RAGE-mediated transport, tau phosphorylation, Amyloid beta Deposition
Abstract: Alzheimers disease (AD) is the most common age-associated neurodegenerative disease in the world. The major neuropathological features of AD are synaptic loss, neuronal loss, neurofibrillary tangles and the deposition of amyloid- β (Aβ) as plaques and in cerebral blood vessels. Numerous Aβ targeting therapeutic approaches have been shown to prevent amyloid deposition and resulting in cognitive improvement in transgenic mouse models of AD. Some of these approaches are currently in early clinical trials. It remains to be seen if these approaches will be proven effective in patients. Future anti-AD therapies will likely be multi-modal and individually tailored depending on the patients immune status, genetic background and their amyloid burden, as determined by imaging studies using Aβ specific labeling ligands. Preclinical data suggests that it will be much more feasible to prevent AD related pathology, then to clear existing pathology, making early diagnosis critically important.
Export Options
About this article
Cite this article as:
Marcin Sadowski and Thomas Wisniewski , Disease Modifying Approaches for Alzheimers Pathology, Current Pharmaceutical Design 2007; 13 (19) . https://dx.doi.org/10.2174/138161207781039788
DOI https://dx.doi.org/10.2174/138161207781039788 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inflammatory Markers Associated With Diabetes Mellitus – Old and New Players
Current Pharmaceutical Design MEFV Mutation Carriers and Diseases Other than Familial Mediterranean Fever: Proved and Non-Proved Associations; Putative Biological Advantage
Current Drug Targets - Inflammation & Allergy The Role of Alpha-lipoic Acid Supplementation in the Prevention of Diabetes Complications: A Comprehensive Review of Clinical Trials
Current Diabetes Reviews Adverse Cutaneous Reactions of Systemic Antihistamines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Genetics of Small-Vessel Disease
Current Medicinal Chemistry Expression, Distribution and Regulation of Phosphodiesterase 5
Current Pharmaceutical Design Cannabinoids and Myocardial Ischemia: Novel insights, Updated Mechanisms, and Implications for Myocardial Infarction
Current Medicinal Chemistry Coronary Microvascular Dysfunction and Heart Failure with Preserved Ejection Fraction - implications for Chronic Inflammatory Mechanisms
Current Cardiology Reviews Inflammation-Induced Thrombosis: Mechanisms, Disease Associations and Management
Current Pharmaceutical Design Foreword: The Year in Review: Comments on Plants, Cyclodextrins, Microbiota, and Diabetes
Current Pharmaceutical Design Modulation of Plasma Non Enzimatic Antioxidant Capacity (NEAC) by Plant Foods: the Role of Polyphenol
Current Topics in Medicinal Chemistry Neurotuberculosis: An Overview
Central Nervous System Agents in Medicinal Chemistry Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry MutS Homologues hMSH4 and hMSH5: Genetic Variations, Functions, and Implications in Human Diseases
Current Genomics Voltage-Gated Sodium Channel Blockers as Immunomodulators
Recent Patents on CNS Drug Discovery (Discontinued) Current Update on Eosinophilic Lung Diseases and Anti-IL-5 Treatment
Recent Patents on Anti-Infective Drug Discovery Neuroprotection by Diazoxide in Animal Models for Cerebrovascular Disorders
Vascular Disease Prevention (Discontinued) Primary Antiphospholipid Syndrome and Pulmonary Hypertension
Current Pharmaceutical Design Resurgence of Herbal Antihypertensives in Management of Hypertension
Current Hypertension Reviews <i>Epimedium brevicornum</i> Maxim and its Efficacy in the Treatment of Sexual Dysfunction
The Natural Products Journal